Abstract

Comprehensive genomic analysis of paired primary tumors and their metastatic lesions may provide new insights into the biology of metastatic processes and therefore guide the development of novel strategies for intervention. To date, our knowledge of the genetic divergence and phylogenetic relationships in gallbladder cancer (GBC) is limited. We performed whole exome sequencing for 5 patients with primary tumor, metastatic lymph node (LNM) and corresponding normal tissue. Mutations, mutation signatures and copy number variations were analyzed with state-of-art bioinformatics methods. Phylogenetic tree was also generated to infer metastatic pattern. Five driver mutations were detected in these patients. Among which, TP53 was the only shared mutation between primary tumor and LNM. Although tumor mutational burden was comparable between primary tumor and LNM, higher mutation burden was observed in LNM of one patient. Copy number variations (CNVs) burden was higher in LNM than their primary tumor. Phylogenetic analysis indicated both linear and parallel progression of metastasis exist in these patients. TP53 mutation and CNVs were homogenously between primary tumor and LNM. High consistence of genetic landscape were shown between primary tumor and LNM in GBC. However, heterogenicity still exist between primary tumor and LNM in particular patients in term of driver mutation, TMB and CNV burden. Phylogenetic analysis indicated both Linear and parallel progression of metastasis were exist among these patients.

Highlights

  • Gallbladder cancer is the most common malignant tumor of the biliary tract worldwide

  • High consistence of genetic landscape were shown between primary tumor and lymph node metastasis (LNM) in gallbladder cancer (GBC)

  • Heterogenicity still exist between primary tumor and LNM in particular patients in term of driver mutation, tumor mutational burden (TMB) and copy number variations (CNV) burden

Read more

Summary

Introduction

Gallbladder cancer is the most common malignant tumor of the biliary tract worldwide. Most GBCs, are discovered incidentally at routine cholecystectomy or present as advanced stage disease. Less than 20% of gallbladder cancer is eligible for potentially curative surgical resection at diagnosis.[2] The overall prognosis of GBC is very poor, despite recent improvement of chemotherapy, molecular targeted therapy and aggressive surgical resection with advances in perioperative care[3]. Regional nodal status and the depth of tumor invasion (T status) are the two most important prognostic factors.[4] Genetic landscape studies facilitated by generation sequencing (NGS) has improved our understanding of this disease in terms of oncogenesis, metastasis and therapeutic. Our knowledge of the genetic divergence and phylogenetic relationships in gallbladder cancer (GBC) is limited

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.